Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Integrated biopharmaceutical company focused on oncology drug discovery, clinical trials, manufacturing, and commercialization in China.
EOC Pharma Group is an integrated biopharmaceutical company focused on the development, manufacturing, and commercialization of oncology products, based in Taizhou, China. The organization operates through a licensing model to build its oncology pipeline, handling clinical trial research, drug discovery, regulatory registration, and sales promotion. To support its operations, the company maintains an 8,000 square meter cGMP manufacturing facility and leverages a network of approximately 1,000 sales representatives through its parent company. EOC Pharma Group has secured financial backing from investors such as Everest Venture and established strategic licensing agreements with pharmaceutical partners including Shionogi and its parent organization, Eddingpharm. The firm is currently advancing multiple clinical trials, including a study with an expected endpoint in August 2025, targeting neoplasms and digestive system disorders. EOC Pharma Group was founded in 2010 by Xin Ni and Xiao Ming Zou.
EOC Pharma Group has raised $103.0M across 2 funding rounds.
EOC Pharma Group has raised $103.0M in total across 2 funding rounds.
EOC Pharma Group has raised $103.0M in total across 2 funding rounds.
EOC Pharma Group's investors include Beijing Taikang Investment, Hongshan Capital Group (Sequoia Capital China), H&Q Asia Pacific.
EOC Pharma Group has raised $103.0M across 2 funding rounds. Most recently, it raised $71.0M Series C in December 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 2, 2019 | $71M Series C | — | — | Announced |
| Nov 7, 2017 | $32M Series B | Beijing Taikang Investment | Hongshan Capital Group (Sequoia Capital China), H&Q Asia Pacific | Announced |